Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with

  • 0 views
  • 04 Jun, 2021
  • 14 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

radiopharmaceutical
nervous
interleukins
palbociclib
cancer
  • 990 views
  • 23 Jun, 2021
  • 114 locations
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.

KRAS
absolute neutrophil count
carcinoma
platelet count
metastasis
  • 0 views
  • 25 Jan, 2021
  • 1 location
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4

neutrophil count
measurable disease
solid tumour
metastatic pancreatic cancer
  • 63 views
  • 26 Apr, 2021
  • 1 location